U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07352423) titled 'Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants' on Jan. 12.
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.
Study Start Date: Feb. 24
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Participants
Intervention:
DRUG: ALXN2230
Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion.
DRUG: Placebo
Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion.
Rec...